Soligenix initiates a phase 2 clinical trial of sgx945 (dusquetide) for the treatment of behÇet's disease

Study dus-aubd-01 opens patient enrollment princeton, n.j. , nov. 14, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened patient enrollment for its phase 2 study (protocol number dus-aubd-01) evaluating sgx945 (dusquetide) in the treatment of behÇet's disease.
SNGX Ratings Summary
SNGX Quant Ranking